Zolbetuximab Loses GLEAM In Pancreatic Cancer

Rising CLDN18.2 Competition From China

 
• By Lisa Takagi
  
zolbetuximab p2 pancreatic
Zolbetuximab's P2 failure for pancreatic cancer treatment may shift the global competition, which largely takes place in China. (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Anticancer

More from Japan